Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,231.94 +46.23 (+3.90%)
Official Closing Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock ↗
Lilly's pipeline is on track to pick up a handful of interesting new programs. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
Will this pharma company become a new leader in the weight loss market? 
Via The Motley Fool
News headline image
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth ↗
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap. 
Via The Motley Fool
Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentals ↗
Via Chartmill
Eli Lilly (NYSE:LLY): High-Growth Stock with Strong Technical and Fundamental Momentum ↗
Via Chartmill
News headline image
Only 2 "Magnificent Seven" Stocks Are Beating the Market This Year. What's Going On? ↗
The market has hit new records this year, but it isn't the "Magnificent Seven" stocks that are leading the way. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
4 Stocks That Can 4x Your Money in 4 Years ↗
Quadrupling your money in four years is an incredible rate of return. 
Via The Motley Fool
News headline image
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs ↗
The company isn't resting on its laurels. 
Via The Motley Fool
News headline image
VUG vs. VTI: Which Vanguard ETF Is the Better Buy for Growth Stocks? ↗
Can growth stocks maintain their momentum, or is it time to diversify? 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Where Will Novo Nordisk Stock Be in 3 Years? ↗
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while. 
Via The Motley Fool
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors. 
Via The Motley Fool
Topics ETFs
News headline image
SCHD vs. VIG: Which Dividend ETF Could Build More Wealth Over 20 Years? ↗
The Schwab U.S. Dividend Equity ETF has the superior selection strategy, while the Vanguard Dividend Appreciation ETF has a bigger growth and tech tilt. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield? ↗
State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio? ↗
State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees. 
Via The Motley Fool
Topics ETFs
News headline image
3 Quality Compounders to Own for Decades
A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season.... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Lo... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
PINK vs. XLV: How Do These Two Health Care ETFs Match Up? ↗
PINK outperformed XLV by 8.7 percentage points over one year, but carries higher fees and volatility. XLV offers lower costs and a higher dividend yield for passive healthcare exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ ↗
Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk. 
Via The Motley Fool
Topics ETFs
News headline image
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? ↗
PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee. 
Via The Motley Fool
Topics ETFs
News headline image
10 Stocks Make Up 60% of This $220 Billion Vanguard ETF. Here's What That Means If the AI Trade Cracks. ↗
How diversified is a 147-stock fund when 10 names hold 60% of the money? 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts ↗
As AI-related stocks weaken, new leaders emerge. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs. 
Via The Motley Fool
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
There are plenty of reasons to love these companies. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
With yields like this, these undervalued tickers aren't apt to remain this cheap forever. 
Via The Motley Fool
Topics Lawsuit
News headline image
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC? ↗
One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all. 
Via The Motley Fool
Topics ETFs
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders ↗
Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.